Moody Lynn & Lieberson LLC Decreases Holdings in Axon Enterprise, Inc (NASDAQ:AXON)

Moody Lynn & Lieberson LLC lessened its holdings in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 26.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,789 shares of the biotechnology company's stock after selling 2,106 shares during the quarter. Moody Lynn & Lieberson LLC's holdings in Axon Enterprise were worth $3,045,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Axon Enterprise by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company's stock valued at $5,019,886,000 after purchasing an additional 275,959 shares in the last quarter. Geode Capital Management LLC raised its stake in Axon Enterprise by 3.7% during the fourth quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company's stock worth $1,095,542,000 after purchasing an additional 65,097 shares during the period. Capital World Investors lifted its holdings in Axon Enterprise by 86.4% in the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock valued at $1,079,145,000 after acquiring an additional 841,772 shares during the last quarter. Alliancebernstein L.P. raised its holdings in Axon Enterprise by 273.8% in the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock valued at $659,128,000 after buying an additional 812,337 shares during the period. Finally, Norges Bank acquired a new position in shares of Axon Enterprise in the 4th quarter worth approximately $482,081,000. Institutional investors and hedge funds own 79.08% of the company's stock.

Axon Enterprise Price Performance

AXON traded up $20.93 during trading on Thursday, hitting $795.48. The company's stock had a trading volume of 268,670 shares, compared to its average volume of 560,874. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $61.93 billion, a price-to-earnings ratio of 192.14, a price-to-earnings-growth ratio of 89.16 and a beta of 1.29. The firm's 50 day moving average price is $733.14 and its two-hundred day moving average price is $634.69. Axon Enterprise, Inc has a 12 month low of $279.02 and a 12 month high of $830.21.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The company had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. During the same period in the prior year, the business posted $1.15 EPS. Axon Enterprise's revenue was up 31.3% on a year-over-year basis. Sell-side analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $540.99, for a total value of $5,409,900.00. Following the completion of the sale, the chief executive officer owned 3,063,982 shares of the company's stock, valued at $1,657,583,622.18. The trade was a 0.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michael Garnreiter sold 5,913 shares of the stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total value of $4,493,880.00. Following the sale, the director directly owned 17,740 shares in the company, valued at approximately $13,482,400. This trade represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 44,642 shares of company stock valued at $30,500,428. Corporate insiders own 4.40% of the company's stock.

Analysts Set New Price Targets

AXON has been the subject of a number of research reports. Bank of America lifted their price objective on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. Needham & Company LLC increased their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Craig Hallum cut Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. The Goldman Sachs Group increased their price target on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Finally, Barclays boosted their target price on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $699.55.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.